DGX

Quest Diagnostics Incorporated (DGX) | Rumor.io

Quest Diagnostics

DGX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,871

Bullish sentiment (50-day avg)91%

Price to earnings ratio25

Market capitalization26.2B

Earnings per share9.42

Dividend yield (TTM)1.45%

Revenue (annual)11B

Net income (annual)1B

Social

What share of all stock conversation is about DGX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Jul 23

Quest Diagnostics reported Q2 2026 revenue of $3.04 billion, up 10.2% year over year, with diluted EPS of $2.84 and adjusted diluted EPS of $3.12.
The company raised full-year 2026 guidance to revenue of $11.95–$12.05 billion and diluted EPS of $9.97–$10.17 (adjusted diluted EPS of $11.05–$11.25).
Quest Diagnostics' stock price surged approximately 10.3% following the earnings beat, driven by partnerships with consumer health players Hims and Oura.

Generated by AI

Sentiment

Of the messages about DGX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +10.67	92.36% -0.27
Bearish	—	—	0% -10.67	7.64% +0.27

Bullish· Oct 21

Quest Diagnostics ($DGX) reported strong Q3 results, beating adjusted EPS and revenue estimates with a 13% YoY increase in adjusted EPS and 13.1% YoY revenue growth.
The company raised its full-year guidance, driven by accelerating organic growth and solid demand for diagnostic services, which is expected to continue in Q4.
Quest Diagnostics' earnings release highlighted revenue of $2.82B, exceeding estimates by $87M, and EPS of $2.60, beating estimates by 3.59%, with a 263.48% YoY growth in EPS.

Bearish· Jan 14

$DGX's guidance was lowered by 9%, resulting in a 24% stock price drop.
The company's stock has crashed over 20% in days, with some expecting a 50-80% correction.
The COVID-19 pandemic is expected to continue destroying the world economy, leading to further declines in $DGX's stock price.

Generated by AI

Topics

Of the messages about DGX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	78.57%	25.42%	7.51%
Macro	—	0%	20.34%	31.65%
Technical Analysis	—	0%	37.29%	0.54%
Analysts	—	0%	10.17%	30.12%
Earnings	—	7.14%	3.39%	30.17%
Controversies	—	14.29%	3.39%	0.01%

Earnings· Oct 21

Quest Diagnostics reported Q3 financial results, beating estimates on adjusted EPS and revenue, with $2.60 EPS and $2.82B revenue.
The company raised FY25 guidance, increasing adjusted EPS to $9.76-$9.84 and sales to $10.96B-$11.00B.
Quest Diagnostics reported strong Q3 growth in clinical and consumer channels, with revenue up 13.1% and net income rising to $245 million.

Analysts· Jul 24

Quest Diagnostics ($DGX) has been reiterated as a "buy" by Citigroup, with a price target of $151.00.
Deutsche Bank has raised its price target for Quest Diagnostics ($DGX) to $150.00, maintaining a "buy" rating.
Mizuho Securities has reaffirmed its "buy" rating for Quest Diagnostics ($DGX), with a price target of $144.00.

Announcements· Jan 6

Nvidia announced the Vera Rubin AI platform at CES 2026, which can be packaged into the DGX SuperPOD, a massive AI supercomputer.
Nvidia CEO Jensen Huang made several significant announcements at CES 2026, including the introduction of the DGX Spark and Personal Agents for AI on every desk.
Nvidia's partners for the DGX platform include a list of Chinese EV makers, with companies like BYD and Xiaomi potentially making the technology mainstream in Chinese cities.

Macro· Apr 27

Nvidia's DGX GB200 supercomputer is a complex system with 600,000 components and 120 kW power consumption, central to its US revenue preservation strategy.
Nvidia plans to commission US-based manufacturing partners to establish facilities and produce components domestically to meet demand and comply with trade regulations.
This strategy aims to mitigate the impact of trade restrictions and ensure the company's ability to serve US customers with its high-performance computing systems.

Generated by AI

Community

Of the messages about DGX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	38.46%	42.39%	8.75%
Newcomers	—	61.54%	57.61%	91.25%

Regulars· Oct 21

Quest Diagnostics reported a Q3 earnings beat, with adjusted EPS of $2.60 vs an estimated $2.50, and revenue of $2.82B vs an estimated $2.74B.
The company raised its FY2025 guidance, with adjusted EPS expected to be $9.76-$9.84 vs a previous estimate of $9.63-$9.83, and sales expected to be $10.96B-$11.00B vs a previous estimate of $10.80B-$10.92B.
Quest Diagnostics' Q3 results showed strong growth in clinical and consumer channels, with revenues up 13.1% from the previous year, and diluted EPS rising to $2.16.

Newcomers· Jul 23

Quest Diagnostics reported strong Q2 results, with revenue of $3.04 billion, up 10.2% year over year, and diluted EPS of $2.84, a 15% increase.
The company raised its full-year 2026 guidance to revenue of $11.95–$12.05 billion and diluted EPS of $9.97–$10.17, with adjusted EPS of $3.12, a 19.1% increase.
The stock price surged 10.3% to $231.40, driven by the strong quarterly earnings beat and raised full-year growth projections, with investors treating the update as materially better than prior expectations.

Generated by AI

News

Quest Diagnostics Stock Gains 36.3% YTD: What's Behind the Rally?

DGX's 36.3% YTD rise reflects momentum in advanced diagnostics, channel growth, AI adoption and cost savings.

5d agoYahoo Finance

Quest Diagnostics (DGX) Could Be 5% Below Fair Value After Apple Health Launch

Quest Diagnostics (DGX) drew fresh attention after announcing an Apple Health integration that allows iPhone and iPad users to order a preventive lab panel with more than 50 biomarkers for US$119. The Apple Health tie-in lands after a strong run in Quest Diagnostics’ shares, with the price up 15.6% over 90 days and 35.1% year to date, even though the last month’s share price return slipped 3.9% as traders reassessed shorter term risk and reward. Scan beyond Quest Diagnostics and see how other...

6d agoYahoo Finance Singapore

Quest Diagnostics Incorporated: Testing Growth Keeps Me Bullish Despite Medicare Headwinds

6d agoSeeking Alpha

Quest Diagnostics (DGX) Stock Could Be 30% Below Fair Value Following Medicare Payment Cut Concerns

Quest Diagnostics has delivered a strong run in recent years, which raises a straightforward question for investors who care about fundamentals. Is the current share price still aligned with the cash the business is expected to generate over time, or has sentiment moved ahead of its underlying economics? Over the past 3 years, Quest Diagnostics has returned 108.9%, which puts real weight on whether that gain is grounded in durable cash flows rather than just multiple expansion. A recent...

7d agoYahoo Finance

Quest Diagnostics Inc. stock underperforms Tuesday when compared to competitors

7d agoMarketWatch

Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026

7d agoYahoo Finance

Also Discussed

Investors talking about DGX also mention

#	Name	Attention
1	Labcorp Holdings Inc.LH	0%0
2	Mainz Biomed N.V.MYNZ	0%new
3	Glacier Bancorp Inc.GBCI	0%0
4	Thermo Fisher Scientific Inc.TMO	0%0
5	Myriad Genetics Inc.MYGN	0%0
6	Qiagen N.V.QGEN	0%+0
7	Illumina Inc.ILMN	0%+0
8	MicroCloud Hologram Inc.HOLO	0%0
9	Phibro Animal Health Corporation Class A Common StockPAHC	0%0
10	Natera, Inc.NTRA	0%-0.01

Quest Diagnostics Incorporated

Healthcare
Diagnostics & Research

Quest Diagnostics Incorporated is a healthcare diagnostics company that provides diagnostic testing and related information services. Quest Diagnostics supports physicians, hospitals, patients, health plans, employers, and government agencies with routine clinical testing, advanced specialty testing, anatomic pathology, and consumer-ordered testing services. Its offerings include laboratory testing for areas such as cancer, heart disease, diabetes, infectious diseases, and genetic conditions, along with services for drug and alcohol screening, risk assessment, and healthcare information technology. The company operates a broad network of laboratories and patient service centers across the United States, helping connect sample collection, analysis, and reporting within the medical care process. Quest Diagnostics Incorporated plays a central role in the healthcare market by providing data and laboratory insights that support diagnosis, treatment decisions, and ongoing health management.

Website

Location

500 Plaza Drive

Secaucus, NJ, 07094

United States

Social

What share of all stock conversation is about DGX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Jul 23

Quest Diagnostics reported Q2 2026 revenue of $3.04 billion, up 10.2% year over year, with diluted EPS of $2.84 and adjusted diluted EPS of $3.12.
The company raised full-year 2026 guidance to revenue of $11.95–$12.05 billion and diluted EPS of $9.97–$10.17 (adjusted diluted EPS of $11.05–$11.25).
Quest Diagnostics' stock price surged approximately 10.3% following the earnings beat, driven by partnerships with consumer health players Hims and Oura.

Generated by AI

Sentiment

Of the messages about DGX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +10.67	92.36% -0.27
Bearish	—	—	0% -10.67	7.64% +0.27

Bullish· Oct 21

Quest Diagnostics ($DGX) reported strong Q3 results, beating adjusted EPS and revenue estimates with a 13% YoY increase in adjusted EPS and 13.1% YoY revenue growth.
The company raised its full-year guidance, driven by accelerating organic growth and solid demand for diagnostic services, which is expected to continue in Q4.
Quest Diagnostics' earnings release highlighted revenue of $2.82B, exceeding estimates by $87M, and EPS of $2.60, beating estimates by 3.59%, with a 263.48% YoY growth in EPS.

Bearish· Jan 14

$DGX's guidance was lowered by 9%, resulting in a 24% stock price drop.
The company's stock has crashed over 20% in days, with some expecting a 50-80% correction.
The COVID-19 pandemic is expected to continue destroying the world economy, leading to further declines in $DGX's stock price.

Generated by AI

Topics

Of the messages about DGX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	78.57%	25.42%	7.51%
Macro	—	0%	20.34%	31.65%
Technical Analysis	—	0%	37.29%	0.54%
Analysts	—	0%	10.17%	30.12%
Earnings	—	7.14%	3.39%	30.17%
Controversies	—	14.29%	3.39%	0.01%

Earnings· Oct 21

Quest Diagnostics reported Q3 financial results, beating estimates on adjusted EPS and revenue, with $2.60 EPS and $2.82B revenue.
The company raised FY25 guidance, increasing adjusted EPS to $9.76-$9.84 and sales to $10.96B-$11.00B.
Quest Diagnostics reported strong Q3 growth in clinical and consumer channels, with revenue up 13.1% and net income rising to $245 million.

Analysts· Jul 24

Quest Diagnostics ($DGX) has been reiterated as a "buy" by Citigroup, with a price target of $151.00.
Deutsche Bank has raised its price target for Quest Diagnostics ($DGX) to $150.00, maintaining a "buy" rating.
Mizuho Securities has reaffirmed its "buy" rating for Quest Diagnostics ($DGX), with a price target of $144.00.

Announcements· Jan 6

Nvidia announced the Vera Rubin AI platform at CES 2026, which can be packaged into the DGX SuperPOD, a massive AI supercomputer.
Nvidia CEO Jensen Huang made several significant announcements at CES 2026, including the introduction of the DGX Spark and Personal Agents for AI on every desk.
Nvidia's partners for the DGX platform include a list of Chinese EV makers, with companies like BYD and Xiaomi potentially making the technology mainstream in Chinese cities.

Macro· Apr 27

Nvidia's DGX GB200 supercomputer is a complex system with 600,000 components and 120 kW power consumption, central to its US revenue preservation strategy.
Nvidia plans to commission US-based manufacturing partners to establish facilities and produce components domestically to meet demand and comply with trade regulations.
This strategy aims to mitigate the impact of trade restrictions and ensure the company's ability to serve US customers with its high-performance computing systems.

Generated by AI

Community

Of the messages about DGX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	38.46%	42.39%	8.75%
Newcomers	—	61.54%	57.61%	91.25%

Regulars· Oct 21

Quest Diagnostics reported a Q3 earnings beat, with adjusted EPS of $2.60 vs an estimated $2.50, and revenue of $2.82B vs an estimated $2.74B.
The company raised its FY2025 guidance, with adjusted EPS expected to be $9.76-$9.84 vs a previous estimate of $9.63-$9.83, and sales expected to be $10.96B-$11.00B vs a previous estimate of $10.80B-$10.92B.
Quest Diagnostics' Q3 results showed strong growth in clinical and consumer channels, with revenues up 13.1% from the previous year, and diluted EPS rising to $2.16.

Newcomers· Jul 23

Quest Diagnostics reported strong Q2 results, with revenue of $3.04 billion, up 10.2% year over year, and diluted EPS of $2.84, a 15% increase.
The company raised its full-year 2026 guidance to revenue of $11.95–$12.05 billion and diluted EPS of $9.97–$10.17, with adjusted EPS of $3.12, a 19.1% increase.
The stock price surged 10.3% to $231.40, driven by the strong quarterly earnings beat and raised full-year growth projections, with investors treating the update as materially better than prior expectations.

Generated by AI

Quest Diagnostics

Social

Jul 23

Bullish· Oct 21

Bearish· Jan 14

Earnings· Oct 21

Analysts· Jul 24

Announcements· Jan 6

Macro· Apr 27

Regulars· Oct 21

Newcomers· Jul 23

Quest Diagnostics Stock Gains 36.3% YTD: What's Behind the Rally?

Quest Diagnostics (DGX) Could Be 5% Below Fair Value After Apple Health Launch

Quest Diagnostics Incorporated: Testing Growth Keeps Me Bullish Despite Medicare Headwinds

Quest Diagnostics (DGX) Stock Could Be 30% Below Fair Value Following Medicare Payment Cut Concerns

Quest Diagnostics Inc. stock underperforms Tuesday when compared to competitors

Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026

Also Discussed

Quest Diagnostics Incorporated

Company Information

Location

Quest Diagnostics Stock Gains 36.3% YTD: What's Behind the Rally?

Quest Diagnostics (DGX) Could Be 5% Below Fair Value After Apple Health Launch

Quest Diagnostics Incorporated: Testing Growth Keeps Me Bullish Despite Medicare Headwinds

Quest Diagnostics (DGX) Stock Could Be 30% Below Fair Value Following Medicare Payment Cut Concerns

Quest Diagnostics Inc. stock underperforms Tuesday when compared to competitors

Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026

Also Discussed

Social

Jul 23

Bullish· Oct 21

Bearish· Jan 14

Earnings· Oct 21

Analysts· Jul 24

Announcements· Jan 6

Macro· Apr 27

Regulars· Oct 21

Newcomers· Jul 23